论文部分内容阅读
目的:回顾性分析CT引导下经皮微波消融(CT-MWA)治疗特殊部位小肝癌的临床疗效及安全性。方法:对2009年8月至2015年5月行CT-MWA治疗的36例小肝癌患者的临床资料进行回顾性分析。分析总结微波消融治疗小肝癌的1、2、3年生存率、完全消融率、局部进展率、并发症及不良反应。结果:36个小病灶行CT-MWA治疗的成功率和完全消融率分别为97.22%(35/36)和88.89%(32/36)。术后轻度肝功能异常5例,肝区疼痛轻度6例、中度3例、重度0例,恶心呕吐3例,食欲下降5例,腹胀3例,发热7例。中位局部无复发时间为15.22个月。术后3、6、12个月及1年以上的肿瘤局部进展率分别为5.56%(2/36)、5.56%(2/36)、11.11%(4/36)、19.44%(7/36)。36例患者的1、2、3生存率分别为86.67%(31/36)、58.33%(21/36)、47.22%(17/36)。结论:CT-MWA治疗特殊部位小肝癌是一种安全有效的微创治疗方法。
Objective: To retrospectively analyze the clinical efficacy and safety of CT-MWA-guided percutaneous microwave ablation (CT-MWA) for the treatment of small hepatocellular carcinoma in special sites. Methods: The clinical data of 36 patients with small hepatocellular carcinoma treated with CT-MWA from August 2009 to May 2015 were retrospectively analyzed. Analyze and summarize the 1-, 2-, 3-year survival rate, complete ablation rate, local progression rate, complications, and adverse reactions of microwave ablation for small hepatocellular carcinoma. Results: The success rate and complete ablation rate of CT-MWA in 36 small lesions were 97.22% (35/36) and 88.89% (32/36), respectively. Mild liver function abnormalities were observed in 5 cases. Mild liver pain was found in 6 cases, moderate in 3 cases, severe in 0 cases, nausea and vomiting in 3 cases, loss of appetite in 5 cases, abdominal distention in 3 cases, and fever in 7 cases. The median time without local recurrence was 15.22 months. The local tumor progression rates at 3, 6, 12 months and more than 1 year after surgery were 5.56% (2/36), 5.56% (2/36), 11.11% (4/36), and 19.44% (7/36). ). The 1, 2, and 3 survival rates in 36 patients were 86.67% (31/36), 58.33% (21/36), and 47.22% (17/36), respectively. Conclusion: CT-MWA is a safe and effective minimally invasive treatment for small hepatocellular carcinoma in special sites.